– February 1, 2007
February 1, 2007
View Issues
-
Promising Long-Term Results of Imatinib for CML
Imatinib inhibits the BCR/ABL tyrosine kinase in CML, leading to improved responses over standard therapy. This report provides 5 year follow-up from the seminal IRIS study of upfront imatinib for chronic phase CML among the 553 patients randomized to 400 mg of imatinib. -
Trastuzumab in The Adjuvant Treatment of Breast Cancer: New Evidence from The HERA Study
Trastuzumab has previously been demonstrated to be active against HER2 positive breast cancer when used in the metastatic setting. -
Having Sons Reduces The Risk of Prostrate Cancer
In a family-based research cohort, men were followed for up to 40 years after the birth of their children, and those with only daughters had a 40% higher risk of prostate cancer compared with men with at least one son. -
Decline in Breast Cancer and Reduced Use of Hormone Therapy
Breast cancer statistics indicate a rapid decrease in prevalence immediately after the publicity surrounding the reports from the Women's Health Initiative. -
Defining Prognostic Features in Triple-Negative Breast Cancer
Breast cancers that are "triple-negative" (ie, ER, PR, HER2-negative) are considered high risk, yet there remains variability, with some demonstrating less malignant features than others. -
Pharmacology Watch
Several important papers have been published in the last 2 months, none more important than the realization that breast cancer rates have dropped precipitously since the publication of the Women's Health Initiative (WHI) in 2002. -
Clinical Briefs in Primary Care Supplement